| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6207640 | IPSEN INC | Treatment of partial growth hormone insensitivity syndrome |
Apr, 2014
(10 years ago) | |
| US5824642 | IPSEN INC | Treatment of partial growth hormone insensitivity syndrome |
Jul, 2014
(9 years ago) | |
| US5681814 | IPSEN INC | Formulated IGF-I Composition |
Sep, 2017
(6 years ago) | |
Increlex is owned by Ipsen Inc.
Increlex contains Mecasermin Recombinant.
Increlex has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Increlex are:
- US6207640
- US5824642
- US5681814
Increlex was authorised for market use on 30 August, 2005.
Increlex is available in injectable;subcutaneous dosage forms.
Increlex can be used as treatment of primary igf-1 deficiency.
The generics of Increlex are possible to be released after 18 September, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Aug 30, 2012 |
Drugs and Companies using MECASERMIN RECOMBINANT ingredient
Market Authorisation Date: 30 August, 2005
Treatment: Treatment of primary igf-1 deficiency
Dosage: INJECTABLE;SUBCUTANEOUS
More Information on Dosage
INCRELEX family patents
